[Competing risk largely explains the drop in admissions for acute cardiovascular disease during the COVID-19 pandemic. Response] [0.03%]
[对“在COVID-19疫情期间，急性心血管疾病的住院率大幅下降的主要解释是竞争风险”的回复]
Aida Ribera,Josepa Mauri Ferré,Rafael Romaguera
Aida Ribera
[A new inflammatory-microthrombotic syndrome as an explanation for thrombotic complications in patients with COVID-19] [0.03%]
COVID-19患者发生血栓性并发症的一种新的炎症-微血栓形成综合征解释
Francisco Valga,Nicanor Vega-Díaz,Manuel Macía et al.
Francisco Valga et al.
Iñigo Pereiro Lili,Ainara Lozano Bahamonde,Nora García Ibarrondo
Iñigo Pereiro Lili
[Renin-angiotensin system blockers and outcomes during hydroxychloroquine treatment in patients hospitalized for COVID-19 pneumonia] [0.03%]
住院COVID-19肺炎患者使用羟氯喹治疗期间肾素血管紧张素系统阻滞剂与结果的关系
Giuseppe Di Tano,Renata De Maria,Marco Loffi et al.
Giuseppe Di Tano et al.
Ignacio Ferreira-González
Ignacio Ferreira-González
Meylin Caballeros Lam,Ana de la Fuente Villena,Aitor Hernández Hernández et al.
Meylin Caballeros Lam et al.
[Competing risk largely explains the drop in admissions for acute cardiovascular disease during the COVID-19 pandemic] [0.03%]
[竞争风险在很大程度上解释了COVID-19大流行期间急性心血管疾病住院率的下降]
Luis Rodríguez-Padial,Miguel Ángel Arias
Luis Rodríguez-Padial
[Adults with congenital heart disease during the coronavirus disease 2019 (COVID-19) pandemic: are they at risk?] [0.03%]
[新型冠状病毒肺炎(COVID-19)大流行期间先天性心脏病成人患者感染的风险评估]
Pastora Gallego,Francisco Javier Ruperti-Repilado,Markus Schwerzmann
Pastora Gallego
[Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry] [0.03%]
血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂对西方人群COVID-19的影响。CARDIOVID注册表
Diego López-Otero,Javier López-Pais,Carla Eugenia Cacho-Antonio et al.
Diego López-Otero et al.
Introduction and objectives: Coronavirus disease (COVID-19) has been designated a global pandemic by the World Health Organization. It is unclear whether previous treatment with angiotensin-converting enzyme inhibitors (A...